Sensitive quantification of atomoxetine in human plasma by HPLC with fluorescence detection using 4-(4,5-diphenyl-1H-imidazole-2-yl) benzoyl chloride derivatization.
The first HPLC-fluorescence method for the determination of atomoxetine in human plasma was developed and validated. Atomoxetine was derivatized with 4-(4,5-diphenyl-1H-imidazol-2-yl) benzoyl chloride (DIB-Cl) under mild conditions, and separated isocratically on a C18 column using a HPLC system with fluorescence detection (lambdaex: 318 nm, lambdaem: 448 nm). A linear calibration curve was obtained over the concentration range 1-1000 ng/mL (r=0.999). The limit of detection (S/N=3) was 0.3 ng/mL. The relative standard deviations of intra-day and inter-day variations were < or =8.30% and 7.47%, respectively. This method is rapid, sensitive, and suitable for both basic and clinical studies of atomoxetine.
Zhu
Hao-Jie
HJ
Laboratory of Drug Disposition and Pharmacogenetics, Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA.
Wang
Jun-Sheng
JS
Donovan
Jennifer L
JL
DeVane
C Lindsay
CL
Gibson
Bryan B
BB
Markowitz
John S
JS
D018759:Adrenergic Uptake Inhibitors / Q000097:blood*; D000069445:Atomoxetine Hydrochloride; D001565:Benzoates; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D007093:Imidazoles / Q000737:chemistry*; D011437:Propylamines / Q000097:blood*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence / Q000379:methods*
C114684:4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride; D018759:Adrenergic Uptake Inhibitors; D001565:Benzoates; D007093:Imidazoles; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride